Certain Products Containing Tirzepatide and Products Purporting To Contain Tirzepatide; Notice of Institution of Investigation, 82914-82915 [2023-26058]
Download as PDF
82914
Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
published in the Federal Register as
provided in § 207.21 of the
Commission’s rules, upon notice from
the U.S. Department of Commerce
(‘‘Commerce’’) of affirmative
preliminary determinations in the
investigations under §§ 703(b) or 733(b)
of the Act, or, if the preliminary
determinations are negative, upon
notice of affirmative final
determinations in those investigations
under §§ 705(a) or 735(a) of the Act.
Parties that filed entries of appearance
in the preliminary phase of the
investigations need not enter a separate
appearance for the final phase of the
investigations. Industrial users, and, if
the merchandise under investigation is
sold at the retail level, representative
consumer organizations have the right
to appear as parties in Commission
antidumping and countervailing duty
investigations. The Secretary will
prepare a public service list containing
the names and addresses of all persons,
or their representatives, who are parties
to the investigations.
Background
On October 4, 2023, the U.S.
Aluminum Extruders Coalition
(consisting of Alexandria Extrusion
Company, Alexandria, Minnesota; APEL
Extrusions Inc., Coburg, Oregon;
Bonnell Aluminum, Newnan, Georgia;
Brazeway, Adrian, Michigan; Custom
Aluminum Products, South Elgin,
Illinois; Extrudex Aluminum, North
Jackson, Ohio; International Extrusions,
Garden City, Michigan; Jordan
Aluminum Company, Memphis,
Tennessee; M–D Building Products,
Oklahoma City, Oklahoma; Merit
Aluminum, Corona, California; MI
Metals, Oldsmar, Florida; Pennex
Aluminum, Wellsville, Pennsylvania;
Tower Extrusions, Olney, Texas; and
Western Extrusions, Carrollton, Texas)
and the United Steel, Paper and
Forestry, Rubber, Manufacturing,
Energy, Allied Industrial and Service
Workers International Union,
Pittsburgh, Pennsylvania filed petitions
with the Commission and Commerce,
alleging that an industry in the United
States is materially injured or
threatened with material injury by
reason of subsidized imports of
aluminum extrusions from China,
Indonesia, Mexico, and Turkey and
LTFV imports of aluminum extrusions
from China, Colombia, Dominican
Republic, Ecuador, India, Indonesia,
Italy, Malaysia, Mexico, South Korea,
Taiwan, Thailand, Turkey, United Arab
Emirates and Vietnam. Accordingly,
effective October 4, 2023, the
Commission instituted countervailing
duty investigation Nos. 701-TA-695–698
VerDate Sep<11>2014
17:43 Nov 24, 2023
Jkt 262001
and antidumping duty investigation
Nos. 731-TA-1643–1657 (Preliminary).
Notice of the institution of the
Commission’s investigations and of a
public conference to be held in
connection therewith was given by
posting copies of the notice in the Office
of the Secretary, U.S. International
Trade Commission, Washington, DC,
and by publishing the notice in the
Federal Register of October 13, 2023 (88
FR 71020). The Commission conducted
its conference on October 25, 2023. All
persons who requested the opportunity
were permitted to participate.
The Commission made these
determinations pursuant to §§ 703(a)
and 733(a) of the Act (19 U.S.C.
1671b(a) and 1673b(a)). It completed
and filed its determinations in these
investigations on November 20, 2023.
The views of the Commission are
contained in USITC Publication 5477
(November 2023), entitled Aluminum
Extrusions from China, Colombia,
Dominican Republic, Ecuador, India,
Indonesia, Italy, Malaysia, Mexico,
South Korea, Taiwan, Thailand, Turkey,
United Arab Emirates, and Vietnam:
Investigation Nos. 701–TA–695–698 and
731–TA–1643–1657 (Preliminary).
By order of the Commission.
Issued: November 21, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023–26057 Filed 11–24–23; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1377]
Certain Products Containing
Tirzepatide and Products Purporting
To Contain Tirzepatide; Notice of
Institution of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
SUMMARY: Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
October 19, 2023, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Eli Lilly and Company of
Indianapolis, Indiana. A supplement
was filed on November 10, 2023. The
complaint, as supplemented, alleges
violations of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain products containing tirzepatide
and products purporting to contain
tirzepatide by reason of the
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
infringement of U.S. Trademark
Registration No. 6,809,369 (‘‘the ’369
mark’’). The complaint further alleges
that an industry in the United States
exists as required by the applicable
Federal Statute. The complaint also
alleges violations of section 337 based
upon the importation into the United
States, or in the sale of certain products
containing tirzepatide and products
purporting to contain tirzepatide by
reason of false designation of source and
false and misleading advertising, the
threat or effect of which is to destroy or
substantially injure an industry in the
United States. The complainant requests
that the Commission institute an
investigation and, after the
investigation, issue a general exclusion
order or, in the alternative, a limited
exclusion order, and cease and desist
orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2023).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
November 20, 2023, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(A) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (3) by reason of
E:\FR\FM\27NON1.SGM
27NON1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices
false designation of source and false and
misleading advertising, the threat or
effect of which is to destroy or
substantially injure an industry in the
United States;
(2) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(C) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (3) by reason of
infringement of the ’369 mark, and
whether an industry in the United
States exists as required by subsection
(a)(2) of section 337;
(3) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘products containing
tirzepatide or purporting to contain
tirzepatide sold in powdered or
constituted form’’;
(4) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is:
Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, IN 46285
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Arctic Peptides LLC, 2104 NE Oak Dr,
Ankeny, IA 50021
Audrey Beauty Co., Flat C 23/F Lucky
Plaza, 315–321 Lockhart Road, Wan
Chai, Hong Kong, China
Biolabshop Limited, 25 Scotforth Road,
Lancaster, PR1 4XX, United
Kingdom
Mew Mews Company Limited, RM C1
11/F Blk 1 152 Tai Lin Pai Road,
Golden Dragon IND Ctr., Kwai
Chung, New Territories, Hong
Kong, China
Strate Labs LLC, 18482 Kuykendahl
Road #123, Spring, TX 77379–8123
Steroide Kaufen, W. Polna 2017, 15–698
Bialystok, Poland
Super Human Store, Passeig Del Taulat
267, 5O 4A, Barcelona 08019, Spain
Supopeptide, 371 Little Falls Road Ste
4, Cedar Grove, NJ 07009
Triggered Supplements LLC, (d/b/a The
Triggered Brand), 1361 S Martin
Luther King Jr Ave., Clearwater, FL
33756
VerDate Sep<11>2014
17:43 Nov 24, 2023
Jkt 262001
Unewlife, 371 Little Falls Road Ste 4,
Cedar Grove, NJ 07009
DEPARTMENT OF JUSTICE
Xiamen Austronext Trading Co., Ltd. (d/
b/a AustroPeptide), Room 3001, No.
5998, Maqing Rd., Haicang District,
Xiamen, Fujian, China 361026
[OMB Number 1110–0NEW]
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street, SW, Suite
401, Washington, DC 20436; and
(5) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainant of the
complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: November 21, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023–26058 Filed 11–24–23; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
82915
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; New
Collection; Under Attack: Assaults on
Our Nation’s Law Enforcement
Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
SUMMARY: The Federal Bureau of
Investigation (FBI), Criminal Justice
Information Services Division,
Department of Justice (DOJ) will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
January 26, 2024
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Kevin Harris/FBI CJIS, 1000 Custer
Hollow Road, Clarksburg, WV 26306,
(304) 625–2000, OSAT@fbi.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
E:\FR\FM\27NON1.SGM
27NON1
Agencies
[Federal Register Volume 88, Number 226 (Monday, November 27, 2023)]
[Notices]
[Pages 82914-82915]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26058]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1377]
Certain Products Containing Tirzepatide and Products Purporting
To Contain Tirzepatide; Notice of Institution of Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on October 19, 2023, under section
337 of the Tariff Act of 1930, as amended, on behalf of Eli Lilly and
Company of Indianapolis, Indiana. A supplement was filed on November
10, 2023. The complaint, as supplemented, alleges violations of section
337 based upon the importation into the United States, the sale for
importation, and the sale within the United States after importation of
certain products containing tirzepatide and products purporting to
contain tirzepatide by reason of the infringement of U.S. Trademark
Registration No. 6,809,369 (``the '369 mark''). The complaint further
alleges that an industry in the United States exists as required by the
applicable Federal Statute. The complaint also alleges violations of
section 337 based upon the importation into the United States, or in
the sale of certain products containing tirzepatide and products
purporting to contain tirzepatide by reason of false designation of
source and false and misleading advertising, the threat or effect of
which is to destroy or substantially injure an industry in the United
States. The complainant requests that the Commission institute an
investigation and, after the investigation, issue a general exclusion
order or, in the alternative, a limited exclusion order, and cease and
desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, may be viewed on the Commission's electronic docket
(EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email
[email protected]. Hearing impaired individuals are advised that
information on this matter can be obtained by contacting the
Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S. International Trade Commission,
telephone (202) 205-2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C. 1337, and in section 210.10 of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10 (2023).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on November 20, 2023, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(A) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain products
identified in paragraph (3) by reason of
[[Page 82915]]
false designation of source and false and misleading advertising, the
threat or effect of which is to destroy or substantially injure an
industry in the United States;
(2) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(C) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain products
identified in paragraph (3) by reason of infringement of the '369 mark,
and whether an industry in the United States exists as required by
subsection (a)(2) of section 337;
(3) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is ``products containing
tirzepatide or purporting to contain tirzepatide sold in powdered or
constituted form'';
(4) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainant is:
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
Arctic Peptides LLC, 2104 NE Oak Dr, Ankeny, IA 50021
Audrey Beauty Co., Flat C 23/F Lucky Plaza, 315-321 Lockhart Road, Wan
Chai, Hong Kong, China
Biolabshop Limited, 25 Scotforth Road, Lancaster, PR1 4XX, United
Kingdom
Mew Mews Company Limited, RM C1 11/F Blk 1 152 Tai Lin Pai Road, Golden
Dragon IND Ctr., Kwai Chung, New Territories, Hong Kong, China
Strate Labs LLC, 18482 Kuykendahl Road #123, Spring, TX 77379-8123
Steroide Kaufen, W. Polna 2017, 15-698 Bialystok, Poland
Super Human Store, Passeig Del Taulat 267, 5O 4A, Barcelona 08019,
Spain
Supopeptide, 371 Little Falls Road Ste 4, Cedar Grove, NJ 07009
Triggered Supplements LLC, (d/b/a The Triggered Brand), 1361 S Martin
Luther King Jr Ave., Clearwater, FL 33756
Unewlife, 371 Little Falls Road Ste 4, Cedar Grove, NJ 07009
Xiamen Austronext Trading Co., Ltd. (d/b/a AustroPeptide), Room 3001,
No. 5998, Maqing Rd., Haicang District, Xiamen, Fujian, China 361026
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street, SW, Suite 401, Washington, DC 20436;
and
(5) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798
(March 19, 2020), such responses will be considered by the Commission
if received not later than 20 days after the date of service by the
complainant of the complaint and the notice of investigation.
Extensions of time for submitting responses to the complaint and the
notice of investigation will not be granted unless good cause therefor
is shown.
Failure of a respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: November 21, 2023.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2023-26058 Filed 11-24-23; 8:45 am]
BILLING CODE 7020-02-P